In order to enhance and focus research on Alzheimer's disease (AD)-specific proteinopathies, the 2018 research framework proposed by the National Institute on Aging and Alzheimer's Association (NIA-AA) recommends that AD be defined by its specific biological signatures that can be documented at autopsy or in living people by biomarkers rather than by its non-specific neurodegenerative and clinical syndromic features. Of the three proposed biomarkers by the NIA-AA research framework in living people (amyloid A-beta (A?), pathologic tau and neurodegeneration), only the two AD-specific proteinopathies (A? and pathologic tau) are considered obligatory for the biological definition of AD, while neurodegeneration, although contribute to cognitive impairment and is part of the fully manifested disease, can also occur in other brain disorders and thus is not specific to AD. The purpose of this harmonized biological definition of AD in living people that includes the preclinical phase is to distinguish AD from other types of brain disorders and dementia, to accelerate and focus research on AD-specific proteinopathies that manifest decades before the clinical manifestation of first symptoms of AD, to enhance better understanding in the underlying mechanisms of AD clinical expression, and to use (and discover) targeted disease modifying interventions that can prevent or delay the onset of AD symptoms. Our ongoing and long-term research interest coincides well with the NIA-AA research framework in living people where we have already performed genome-wide association studies (GWAS) on CSF A?42/tau levels and A? deposition in the brain measured by amyloid-PET and identified known and novel associations in the APOE and non-APOE regions. However, the identified signals do not explain all of the phenotypic variation in the two AD-specific proteinopathies or endophenotypes. Here we propose a collaborative study between leading experts in the field to extend our ongoing efforts to delineate the complete genetic basis of the two AD- specific proteinopathies (A? and pathologic tau) by whole genome sequencing (WGS) using well-characterized and large amyloid-PET and CSF A?42/tau datasets with clinical outcomes of dementia followed by testing the effects of identified significant variants on downstream neurodegeneration markers, and performing extensive bioinformatics and functional studies. The primary objective of this application is to perform and analyze WGS in adequately powered large discovery samples with well-characterized A? and tau data along with clinical outcomes of dementia to identify putative functional variants associated with A? and tau pathologies followed by replications in independent and large samples with A? and tau data (Aims 1-2). We will integrate genetic information to create polygenic risk scores in order to predict A? and tau pathologies and will also examine the role of AD pathology-associated variants with downstream neurodegeneration, neuropathologies that coexist with AD and the risk and age-at-onset of AD (Aim3). Finally, we will functionally characterize genetic association using bioinformatics and in vitro experiments to understand their roles in affecting gene expression as being expression quantitative traits loci, and affecting intracellular and extracellular APP/A? and tau levels. The successful completion of this study will help to identify novel AD-related genes and pathways, and to uncover underlying possible mechanisms for AD.
Alzheimer's disease (AD) is a major public health problem. Currently there is no effective treatment for AD. Genetic studies aiming to improve our understanding of the pathogenesis of AD and underlying mechanisms may contribute to personalized medicine goals and better therapies and/or preventive measures This study is focused to delineate the genetic basis of two AD-specific proteinopathies, amyloid A-beta (A?) and pathologic tau, by whole-genome-sequencing. The successful completion of the proposed comprehensive study using biomarkers of two AD-specific proteinopathies in living people with well characterized amyloid-PET and CSF A?42/tau datasets along with clinical outcomes of dementia followed by functional studies will make a major contribution to our understanding of the pathogenesis of AD and underlying mechanisms, which may contribute to personalized medicine goals and better therapies and/or preventive measures.
